Natixis Advisors
PCVX icon

Natixis Advisors’s Vaxcyte PCVX Stock Holding History

Natixis Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,649
Closed -$553K – 1677
2025
Q1 		$553K Sell
14,649
-888
-6% -$71K ﹤0.01% 1438
2024
Q4 		$1.27M Sell
15,537
-7,160
-32% -$711K ﹤0.01% 1236
2024
Q3 		$2.59M Buy
22,697
+8,606
+61% +$776K 0.01% 1003
2024
Q2 		$1.06M Buy
14,091
+861
+7% +$58.6K ﹤0.01% 1239
2024
Q1 		$904K Sell
13,230
-805
-6% -$55.7K ﹤0.01% 1243
2023
Q4 		$881K Buy
+14,035
New +$729K ﹤0.01% 1244

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Natixis Advisors's PCVX Position: Q2 2025 in Review

Natixis Advisors sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 14,649 shares — an estimated $553K sold.

Natixis Advisors first reported a position in PCVX in Q4 2023 and held it in 6 quarters. The position peaked at $2.59M in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Natixis Advisors reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Natixis Advisors sold 14,649 Vaxcyte shares in Q2 2025, an estimated $553K.
  • Natixis Advisors first reported a position in Vaxcyte in Q4 2023 and held it in 6 quarters.
  • Natixis Advisors's Vaxcyte position peaked at $2.59M in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Natixis Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.